Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Austedo Approved to Treat Chorea in Huntington's Disease

Teva news release; 2017 Apr 3

Teva Pharmaceutical Industries Ltd. has announced that the US Food and Drug Administration (FDA) has approved Austedo (deutetrabenazine) tablets for the treatment of chorea associated with Huntington's disease (HD), a rare and fatal neurodegenerative disorder. Teva Pharmaceutical Industries Ltd is headquartered in Israel.

Indications: Austedo is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of chorea associated with Huntington's disease.

Dosage/administration: The starting dose is 6 mg once daily; titrate up at weekly intervals by 6 mg per day to a tolerated dose that reduces chorea, up to a maximum recommended daily dosage of 48 mg (24 mg twice daily). Total daily dosages of ≥12 mg should be administered in 2 divided doses. Tablets should be administered with food and swallowed whole; they should not be chewed, crushed, or broken.

Adverse reactions: Most common adverse reactions were somnolence, diarrhea, dry mouth, and fatigue.


Teva announces FDA approval of AUSTEDO™ (deutetrabenazine) tablets for the treatment of chorea associated with Huntington’s disease. [news release]. Jerusalem, Israel: Teva Pharmaceutical Industries Ltd. April 3, 2017. Accessed April 13, 2017.

This Week's Must Reads

Vitamin B12, Homocysteine Levels’ Effect on PD, Mov Disord; ePub 2018 Mar 6; Christine, et al

Gray Matter Volume Losses in ET Examined, Parkinsonism Relat Disord; ePub 2018 Mar 10; Cameron, et al

Impaired Set Shifting Linked with Previous Falls, Gait Posture; ePub 2018 Feb 28; McKay, et al

Pseudobulbar Affect Linked to Mood Symptoms in PD, J Neuropsychiatry Clin Neurosci; ePub 2018 Mar 5; Patel, et al

CV Comorbidities Common in Veterans with PD, J Parkinson Dis; ePub 2018 Feb 17; Kotagal, et al

Must Reads in FDA Actions

FDA Permits Marketing of Stroke Alert Software, FDA news release; 2018 Feb 13

Riptide Aspiration System Receives FDA Clearance, Medtronic news release; 2018 Jan 16

FDA Approves Vercise Deep Brain Stimulation System, Boston Scientific news release; 2017 Dec 11